

This article was originally published [here](#)

The gantenerumab arm of phase II/III DIAN-TU-001 study has failed to meet its primary endpoint in people who have an early-onset, inherited form of AD or otherwise known

The post [Roche's gantenerumab fails to meet primary endpoint in AD trial](#) appeared first on [Pharmaceutical Business review](#).